DUBLIN, IRELAND, Aug. 06, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2026 first quarter ended June 30, 2025. Total revenue from continuing operations for the first quarter of fiscal 2026 increased 9% to $1.4 billion compared with $1.3 billion in the first quarter of fiscal 2025. Constant currency organic revenue growth from continuing operations for the first quarter was 8%.
Related Questions
How does the performance of continuing operations offset any declines in discontinued segments?
What is the expected impact of the 9% revenue increase on STE's earnings per share and stock valuation?
How might this earnings report affect analyst sentiment and target price adjustments for STE?
Will the revenue growth lead to increased capital expenditures or M&A activity in the coming quarters?
How does STE's 8% constant currency organic revenue growth compare to peers in the medical device sector?
What were the profit margin and operating expense trends for the quarter, and are they sustainable?
What macroeconomic or currency factors influenced the constant currency growth, and what risks remain?
Is there any guidance on future revenue or profit margins for the remainder of fiscal 2026?